Physicians' Academy for Cardiovascular Education

Efficacy and safety results of long-term extension trial with cardiac myosin inhibitor in HCM

News - Apr. 4, 2022

Updated Cumulative Results Of Treatment With Mavacamten From The EXPLORER-LTE Cohort Of The MAVA-LTE Study In Patients With Obstructive Hypertrophic Cardiomyopathy

Presented at ACC.22 by Florian Rader, MD (Los Angeles, CA, USA)

Introduction and methods

Background

Mavacamten is a selective cardiac myosin inhibitor that reduces cardiac muscle contractility by inhibiting excessive myosin-actin cross-bridge formation. The EXPLORER-HCM phase 3 study has previously shown that mavacamten significantly reduced LVOT gradient and improved symptoms, functional capacity, and health status after 30 weeks compared to placevo in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). The observed safety profile was similar compared to placebo.

MAVA-LTE is an ongoing, 5-year study of mavacamten in obstructive HCM. 231 of 244 patients who completed EXPLORER-HCM enrolled in MAVA-LTE. Florian Rader, MD presented the updated interim results on the long-term safety and efficacy with mavacamten from the EXPLORER-LTE cohort of the MAVA-LTE study at ACC.22.

Methods

All Patients received a starting dose of 5 mg mavacamten after a wash out period. The dose was titrated at weeks 4, 8 and 12 based on site-read echocardiography measures of Valsalva LVOT gradient and LVEF. The dose could also be adjusted at week 24 based on echocardiography measures of post-exercise LVOT gradient. Possible doses were 2.5, 5, 10 or 15 mg. LVEF <50% is a prespecified criterion for temporary discontinuation of the drug. Median follow-up was 62 weeks in the current analysis.

Main results

Efficacy outcomes

Safety outcomes

Conclusion

Interim results of long-term extension study of EXPLORER-HCM showed that treatment with mavacamten resulted in improvements in LVOT gradients, NYHA class, and NT proBNP levels at and beyond 48 weeks in patients with symptomatic obstructive HCM. Rader said that mavacamten was generally well tolerated, and no new safety signals were observed during the longer term follow up.

-Our coverage of ACC.22 is based on the information provided during the congress-

Watch the video with Florian Rader about this study

Share this page with your colleagues and friends: